Akili’s deal to go public via SPAC could close soon

You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday. 

Akili SPAC deal could close soon

Nearly seven months after therapeutic video game maker Akili Interactive announced plans to go public via a merger with a special purpose acquisition company, the deal may be on the verge of closing. The shareholders of Social Capital Suvretta Holdings Corp. I, one of several SPACs helmed by former Facebook exec Chamath Palihapitiya, are meeting today to discuss the proposed merger with Akili. It’s possible that Akili could start trading as early as next week if the final vote clears. The deal would yield Akili at least $162 million in proceeds to fuel the launch of EndeavorRx, Akili’s FDA-cleared game for the treatment of childhood ADHD. That number could go as high as $400 million depending on how many of the SPAC’s shareholders decide to withdraw their money.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In